Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

  • Dirk Vordermark1Email author,
  • Oliver Kölbl1,
  • Klemens Ruprecht2,
  • Giles H Vince3,
  • Klaus Bratengeier1 and
  • Michael Flentje1
BMC Cancer20055:55

https://doi.org/10.1186/1471-2407-5-55

Received: 19 February 2005

Accepted: 30 May 2005

Published: 30 May 2005

Abstract

Background

Hypofractionated stereotactic radiotherapy (HFSRT) is one salvage treatment option in previously irradiated patients with recurrent malignant glioma. We analyzed the results of HFSRT and prognostic factors in a single-institution series.

Methods

Between 1997 and 2003, 19 patients with recurrent malignant glioma (14 glioblastoma on most recent histology, 5 anaplastic astrocytoma) were treated with HFSRT. The median interval from post-operative radiotherapy to HFSRT was 19 (range 3–116) months, the median daily single dose 5 (4–10) Gy, the median total dose 30 (20–30) Gy and the median planning target volume 15 (4–70) ml.

Results

The median overall survival (OS) was 9.3 (1.9-77.6+) months from the time of HFSRT, 15.4 months for grade III and 7.9 months for grade IV tumors (p = 0.029, log-rank test). Two patients were alive at 34.6 and 77.6 months. OS was longer after a total dose of 30 Gy (11.1 months) than after total doses of <30 Gy (7.4 months; p = 0.051). Of five (26%) reoperations, none was performed for presumed or histologically predominant radiation necrosis. Median time to tumor progression after HFSRT on imaging was 4.9 months (1.3 to 37.3) months.

Conclusion

HFSRT with conservative total doses of no more than 30 Gy is safe and leads to similar OS times as more aggressive treatment schemes. In individual patients, HFSRT in combination with other salvage treatment modalities, was associated with long-term survival.

Background

Despite intensive multi-modality treatment including tumor resection, post-operative radiotherapy and frequently adjuvant chemotherapy, the prognosis of malignant glioma continues to be poor. Local recurrence, occuring almost exclusively inside the high-dose volume of post-operative radiotherapy [1], represents a major therapeutic challenge. Re-irradiation as a salvage treatment option is limited by the radiation tolerance of surrounding normal brain tissue. In recent years, single-dose radiosurgery, normofractionated and hypofractionated stereotactic radiotherapy have been investigated as a single modality or in combination with chemotherapy [28]. Re-irradiation appeared to be associated with acceptable toxicity when certain treatment volume and dose limits were respected. Median survival in these series was between 7 and 13 months from the time of salvage radiotherapy suggesting a therapeutic benefit in selected patient groups.

Since published data on hypofractionated stereotactic radiotherapy as a sole modality in recurrent malignant glioma are limited [4, 5, 8], we now analyzed the results of such treatment in 19 consecutive patients treated at a single institution.

Methods

Patients

Between 1997 and 2003, 19 patients were treated with hypofractionated stereotactic radiotherapy (HFSRT) for recurrent malignant glioma at the University of Würzburg, Germany. The patient characteristics are summarized in Table 1. All patients had received previous involved-field radiotherapy with 45 to 61 Gy and 94% of patients had been pretreated with chemotherapy, most often nimustine (ACNU) and teniposide, a combination protocol favored by the Neuro-Oncology Working Group of the German Cancer Society [9].
Table 1

Clinical characteristics of n = 19 consecutive patients treated with hypofractionated stereotactic radiotherapy (HFSRT) for recurrent malignant glioma.

median age (range) at time of HFSRT

50 years

(11–74 years)

male / female

8 (42%)/11(58%)

 

median Karnofsky performance score at time of HFSRT (range)

90

(60–90)

initial histology

  

astrocytoma II°

3 (16%)

 

pure anaplastic astrocytoma III°

4 (21%)

 

anaplastic oligoastrocytoma or oligodendroglioma III°

3 (16%)

 

glioblastoma multiforme IV°

9 (47%)

 

most recent histology before HFSRT

  

anaplastic astrocytoma III°

5 (26%)

 

glioblastoma multiforme IV°

14 (74%)

 

initial surgical procedure

  

resection

15 (79%)

 

biopsy

4 (21%)

 

post-operative radiotherapy

  

1.8–2.0 Gy daily (total dose 54 to 61 Gy)

12 (63%)

 

3 Gy daily (total dose 45 Gy)

2 (11%)

 

2 × 1.8 Gy daily (total dose 54 Gy)

5 (26%)

 

salvage surgery before HFSRT

12 (63%)

 

adjuvant or salvage chemotherapy before HFSRT

  

nimustine / teniposide

12 (63%)

 

temozolomide

5 (26%)

 

other

1 (5%)

 

median interval post-OP radiotherapy to HFSRT (range)

19 months

(3–116 months)

Treatment technique

HFSRT was performed non-invasively using a commercially available relocatable mask system as previously described [10]. For planning CT, 3 mm scans of the brain were obtained after administration of an i. v. contrast agent. Treatment planning was performed using Helax TMS (Nucletron, Veenendal, Netherlands) software. For planning target volume (PTV) definition, a margin of 1 to 3 mm around the contrast-enhancing volume was used. Depending on the shape of the PTV, treatment plans were created containing multiple non-coplanar arcs, multiple non-coplanar fixed fields or combinations of both. The treatment plans were normalized to 100% at the isocenter and prescribed to a median isodose of 80% (range 70 to 90%), enclosing the PTV. Details of treatment planning and dose prescription are given in Table 2.
Table 2

Treatment details of hypofractionated stereotactic radiotherapy (HFSRT) in n = 19 consecutive patients with recurrent malignant glioma.

Median planning target volume (range)

15 ml

(4–70 ml)

Median prescription isodose (range)

80%

(70–90%)

Median single dose (range)

5 Gy

(4–10 Gy)

Median total dose (range)

30 Gy

(20–30 Gy)

Fractionation schedules

  

5 × 4 Gy

2 (11%)

 

4 × 5 Gy

5 (26%)

 

6 × 5 Gy

6 (32%)

 

5 × 6 Gy

5 (26%)

 

2 × 10 Gy

1 (5%)

 

HFSRT technique

  

multiple non-coplanar arcs

5 (26%)

 

multiple non-coplanar fixed fields

11 (58%)

 

combination arcs / fixed fields

3 (16%)

 

median field no. (range)

5

(3–8)

Immediately before the first treatment session, CT simulation was performed as described [10]. Briefly, the isocenter position was verified with regard to bony and parenchymal landmarks and to the contrast enhancing tumor and positioning errors were corrected after attaching the mask system to the treatment table. Treatment was delivered from a Philips SL 75/20 or Siemens Primus linear accelerator (6 MV or 8 MV photons, respectively) equipped with a manual micro-multileaf collimator. Subsequent CT simulations were performed at the discretion of the treating physician depending on the setup error determined at time of the first fraction. HFSRT treatment was performed five days per week. During the HFSRT series, patients were maintained on their previous corticosteroid dose or corticosteroids were started. Daily doses ranged between 32 mg of prednisolone and 40 mg of dexamethasone.

Statistics

The main endpoint of this study was overall survival (OS) from the time of HFSRT. Kaplan-Meier survival curves were calculated for these intervals considering death as an event and patients alive at last follow-up as censored. Subgroups were compared using the log-rank test. Statistical analysis was performed with Statistica 6.1 software (Tulsa, OK, USA). Overall survival from initial diagnosis and time to tumor progression were considered as secondary endpoints. For the analysis of time to recurrence, neuroradiological diagnoses of follow-up CT and MRI scans were used. Imaging was routinely reviewed by an interdisciplinary tumor board which based its recommendations on these studies.

Results

HFSRT was well tolerated and no acute neurotoxicity or deterioration in the general health status was observed. Five of 19 patients were reoperated after HFSRT. In three of these, resection was performed for tumor progression on imaging. Histology showed tumor only in two of these cases and predominant tumor with necrosis in one case. In two patients, Ommaya reservoirs were implanted. Thirteen patients received further chemotherapy after HFSRT. Temozolomide was used in six patients, nimustine / teniposide in four and other multi-agent protocols in three.

For the whole group of n = 19 patients with recurrent malignant glioma, the median overall survival from the time of HFSRT was 9.3 months (range 1.9 to 77.6+ months; Fig. 1). At the time of analysis, two patients were alive at 34.6 months and 77.6 months. One-year and two-year survival rates were 26% and 16%, respectively. Overall survival from time of HFSRT for subgroups is shown in Table 3.
Figure 1

Overall survival of n = 19 patients with recurrent malignant glioma treated with hypofractionated stereotactic radiotherapy (HFSRT), from the time of re-irradiation.

Table 3

Median overall survival from the time of hypofractionated stereotactic radiotherapy (HFSRT) in subgroups of patients with recurrent malignant glioma.

 

n

median (range) overall survival (months)

p

WHO grade (initial histopathology)

   

II or III

10

13.5 (1.9–77.6)

0.036

IV

9

7.4 (4.2–10.8)

 

WHO grade (most recent before HFSRT)

   

III

5

15.4 (1.9–77.6)

0.029

IV

14

7.9 (4.2–38.8)

 

initial surgical procedure

   

biopsy

15

9.3 (4.2–77.6)

0.89

resection

4

9.2 (1.9–34.6)

 

chemotherapy before HFSRT

   

yes

13

9.3 (1.9–77.6)

0.76

no

6

8.9 (7.3–15.4)

 

reoperation before HFSRT

   

yes

12

8.4 (1.9–77.6)

0.93

no

7

9.3 (5.6–34.6)

 

age at time of HFSRT

   

< 50 years

11

11.9 (1.9–77.6)

0.14

> 50 years

8

8.9 (5.0–11.1)

 

Karnofsky performance score at time of HFSRT

   

≥ 90

14

7.9 (4.2–77.6)

0.80

< 90

5

11.9 (1.9–15.4)

 

planning target volume (ml)

   

< 15 ml

9

9.3 (5.2–38.8)

0.59

> 15 ml

10

7.4 (1.9–77.6)

 

interval first RT series to HFSRT

   

> 20 months

9

7.4 (1.9–77.6)

0.90

< 20 months

10

9.3 (5.6–38.8)

 

total HFSRT dose

   

30 Gy

11

11.1 (1.9–77.6)

0.051

< 30 Gy

8

7.4 (4.2–11.9)

 

chemotherapy after HFSRT

   

yes

13

9.3 (1.9–77.6)

0.27

no

6

8.9 (4.2–11.1)

 
WHO grading, both that determined at initial diagnosis of glioma and the most recent before HFSRT, had a significant impact on survival. Patients with a most recent histopathology of a grade III glioma had a median overall survival from the time of HFSRT of 15.4 (1.9 to 77.6) months, those with grade IV tumors of 7.9 (4.2 to 38.8) months (p = 0.029, log-rank test; Fig. 2). A trend toward a beneficial effect of higher total doses (30 Gy vs. <30 Gy) on overall survival was observed (p = 0.051; Table 3, Fig. 3). Median overall survival from the first histological diagnosis of glioma (of any grade) was 40.8 months (12.9 to 135 months). Respective median overall survival times from first diagnosis by initial histological grade were 134.7 (64.5 to 135) months for WHO grade II, 57 (30.8 to 119.4+) months for grade III and 26 (12.9 to 40.8) months for grade IV tumors.
Figure 2

Overall survival from the time of re-irradiation of n = 19 patients with recurrent malignant glioma treated with hypofractionated stereotactic radiotherapy (HFSRT), by WHO grade (most recent histopathology before HFSRT).

Figure 3

Overall survival from the time of re-irradiation of n = 19 patients with recurrent malignant glioma treated with hypofractionated stereotactic radiotherapy (HFSRT), by total dose.

Information on follow-up imaging was available in 15 patients. Tumor progression was first diagnosed on MRI in 11 cases and on CT in four cases. The median interval between HFSRT and documented tumor progression was 4.9 months (1.3 to 37.3 months) in the overall group and 7.6 months (3.9 to 37.3 months) and 4.6 months (1.3 to 29.5 months) in the subgroups with a most recent histology of grade III astrocytoma and glioblastoma, respectively.

Survival times from initial diagnosis for the two living patients were 49.7 and 119.4 months. The patient alive at 119.4 months (77.6 months from HFSRT) is a child first treated with HFSRT at the age of eleven for a fourth recurrence of an anaplastic astrocytoma after multiple resections, fractionated radiotherapy and intensive multi-agent chemotherapy. After further adjuvant chemotherapy, this patient recurred 37 months after HFSRT and has since been treated with another resection, a second series of HFSRT (49 months after the first HFSRT) to a volume adjacent to the initial HFSRT region (7 × 5 Gy, 80% isodose) and implantation of BCNU polymers. The most recent MRI in this patient showed no evidence of tumor recurrence. This patient was the only pediatric case included in the present analysis. The patient alive at 49.7 months from initial diagnosis (34.6 months from HFSRT) was first treated for anaplastic astrocytoma at 34 years with biopsy, involved-field radiotherapy and multi-agent chemotherapy. Twelve months after the first radiotherapy series, HFSRT and sequential temozolomide were given for tumor recurrence.

Discussion

Local recurrence of malignant glioma pretreated with resection, post-operative radiotherapy and frequently with adjuvant chemotherapy is a common problem in clinical practice. Reoperation, re-irradiation and systemic or intratumoral chemotherapy are among the therapeutic options available in this situation. Only the implantation of BCNU polymers at the time of reoperation is supported by randomized trial data, having been shown to be superior to re-resection alone [11]. The benefit of other treatments needs to be evaluated based on phase II data and retrospective analyses which both are prone to bias by patient selection for salvage treatment. A recent large retrospective investigation analyzed the benefit of salvage treatment in patients with glioblastoma multiforme [12]. The authors found that the first, mostly chemotherapeutic, reintervention in this patient group was associated with a doubling in median overall survival from 26 to 61.5 weeks, although selection effects in this series can not be excluded.

Prolongation of survival in recurrent malignant glioma has not been convincingly shown for either re-resection or re-irradiation by interstitial brachytherapy, single-dose radiosurgery or fractionated radiotherapy [13]. Hypofractionated stereotactic radiotherapy (HFSRT) has been proposed as a combination of high-precision treatment with small margins and maximum sparing of normal brain tissue, non-invasive technique and short treatment duration using single fraction doses of 3 Gy to 9 Gy (Table 4).
Table 4

Overview of published results on hypofractionated stereotactic radiotherapy (HFSRT) in patients with recurrent malignant glioma (RT: radiotherapy).

authors

patient number

single dose (Gy)

total dose (Gy)

median tumor volume (ml)

chemo-therapy

overall survival (median)

surgery for toxicity

prognostic factors

comment

Shepherd et al., 1997 [4]

29 ("high-grade astrocy-toma")

5 (daily)

20–50

24 (3–93)

--

10.7 months

6%

initial low-grade histology associated with longer survival

36% steroid dependent toxicity (increased risk >40 Gy)

Glass et al., 1997 [6]

20 (7 grade III, 13 grade IV)

3.5–6 (twice / week)

35–42

14 (2–122)

cisplatin 40 mg/m2 weekly

12.7 months

15% pre-dominant necrosis on re-operation

--

40% treated within 10 weeks of first RT series for ("potential") progression

Hudes et al., 1999 [5]

19 (glio-blastoma)

3–3.5 (daily)

24–35

13 (1–48)

--

10.5 months

0%

"minor response" on imaging associated with ≥30 Gy and ≤20 ml

recurrent or persistent tumors treated, median interval between completion of RT and HFSRT only 3.1 months

Lederman et al., 2000 [7]

88 (glio-blastoma)

4–9 (weekly)

18–36

32.7 (2–150)

paclitaxel 120 mg/m2 (median) weekly

7 months

8% necrosis only at re-operation

volume ≥30 ml associated with longer survival

median time from diagnosis to HFSRT only 6.5 months

Voynov et al., 2002 [8]

10 (5 WHO grade III, 5 grade IV)

5

30

34.7

--

10.1 months

?

--

stereotactic intensity-modulated radiotherapy (IMRT) used

present series

19 (5 WHO grade III, 14 grade IV)

4–10 (daily)

20–30

15 (4–70)

--

9.3 months

0%

WHO grade IV and <30 Gy associated with short survival

median interval post-OP RT to HFSRT 19 months

In the present single-institution series of patients with recurrent malignant glioma, median survival times from the time of HFSRT of 9.3 months (most recent histology grade III 15.4 months, grade IV 7.9 months) were achieved. In published series of HFSRT, applied either as a single modality or in combination with chemotherapy, median overall survival ranged between 7 and 12.7 months (Table 4). Comparability between these series is limited by differences in patient selection and treatment concept. The median total dose of 30 Gy in 5-Gy fractions in the present series is close to the limit of 35 Gy which is thought to be applicable in pre-irradiated patients with acceptable toxicity [4]. However, a total dose of 20 Gy in 4-Gy or 5-Gy fractions, as used in about one third of patients, may be regarded as too low based on recent literature data [4]. Indeed, a trend toward longer survival with total doses of at least 30 Gy was observed (Table 3, Fig. 1C). The finding that no patient in the present series had to be reoperated for symptomatic radiation necrosis also suggests that the dose schedules prescribed were rather conservative. Other potential prognostic factors such as age, Karnofsky performance score or tumor size (planning target volume) were not significant predictors of survival in the present series, possibly due to the limited patient number.

It must be noted that in many patients HFSRT was one element of salvage therapy and further chemotherapy or surgical interventions were performed in 68% and 26% of patients, respectively. In the patients with available imaging information, the median time from HFSRT to tumor progression was approximately five months which may be regarded as an approximation of the lifetime gained by HFSRT in these highly selected patients. In the patient with the longest survival time of 77.6+ months after re-irradiation, a second HFSRT series was performed as well as multiple other treatments, highlighting the benefit of aggressive multi-modality treatment in individual patients. The longest survival time in glioblastoma was 38.8 months from HFSRT, indicating that even in grade IV tumors single patients may survive much longer than expected.

Data from the present series and published reports suggest that efficacy and toxicity are favorable compared to single-dose radiosurgery and the invasive modality of interstitial brachytherapy. While radiosurgery resulted in median overall survival times of 26 to 50 weeks and reoperation rates of 0 to 22%, median overall survival of 47 weeks and reoperation in 41 to 44% (with about 5% of patients showing radionecrosis only) were reported for interstitial brachytherapy [13]. In a recent review of re-irradiation, HFSRT was favored as radiotherapy modality and the following criteria for the application of HFSRT were recommended [14]: good general status (WHO 0–1), at least one year disease-free interval, initial grade II or III histology and maximal tumor diameter 3 cm.

While such criteria may identify patients with the greatest benefit from HFSRT, salvage treatment decisions in recurrent malignant glioma will remain highly individualized. Given the low toxicity of the method, HFSRT may be offered to patients in good general condition with tumor recurrences of limited volume.

Conclusion

HFSRT with moderate total doses of no more than 30 Gy is safe and leads to similar OS times as more aggressive treatment schemes. In individual patients, HFSRT in combination with other salvage treatment modalities, can be associated with long-term survival.

Declarations

Authors’ Affiliations

(1)
Dept. of Radiation Oncology, University of Würzburg
(2)
Dept. of Neurology, University of Würzburg
(3)
Dept. of Neurosurgery, University of Würzburg

References

  1. Oppitz U, Maessen D, Zunterer H, Richter S, Flentje M: 3-D recurrence patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol. 1999, 53: 53-57. 10.1016/S0167-8140(99)00117-6.View ArticlePubMedGoogle Scholar
  2. Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB: Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999, 45: 1133-1141. 10.1016/S0360-3016(99)00336-3.View ArticlePubMedGoogle Scholar
  3. van Kampen M, Engenhart-Cabilic R, Debus J, Fuß M, Rhein B, Wannenmacher M: The value of radiosurgery for recurrent glioblastoma multiforme (German). The Heidelberg experience and review of the literature. Strahlenther Onkol. 1998, 174: 19-24.View ArticleGoogle Scholar
  4. Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M: Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997, 37: 393-398. 10.1016/S0360-3016(96)00455-5.View ArticlePubMedGoogle Scholar
  5. Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ: A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 1999, 43: 291-298. 10.1016/S0360-3016(98)00416-7.View ArticleGoogle Scholar
  6. Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW: Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive or persistent malignant astrocytoma. Am J Clin Oncol. 1997, 20: 226-229. 10.1097/00000421-199706000-00002.View ArticlePubMedGoogle Scholar
  7. Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E, Wrzolek M: Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol. 2000, 23: 155-159. 10.1097/00000421-200004000-00010.View ArticlePubMedGoogle Scholar
  8. Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R: Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol. 2002, 25: 606-611. 10.1097/00000421-200212000-00017.View ArticlePubMedGoogle Scholar
  9. Weller M, Müller B, Koch R, Bamberg M, Krauseneck P, Neuro-Oncology Working Group of the German Cancer Society: Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol. 2003, 21: 3276-3284. 10.1200/JCO.2003.03.509.View ArticlePubMedGoogle Scholar
  10. Willner J, Flentje M, Bratengeier K: CT-simulation in stereotactic brain radiotherapy – analysis of isocenter reproducibility with mask fixation. Radiother Oncol. 1997, 45: 83-88. 10.1016/S0167-8140(97)00135-7.View ArticlePubMedGoogle Scholar
  11. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995, 345: 1008-1012. 10.1016/S0140-6736(95)90755-6.View ArticlePubMedGoogle Scholar
  12. Hau P, Baumgart U, Pfeifer K, Bock A, Jauch T, Dietrich J, Fabel K, Grauer O, Wismeth C, Klinkhammer-Schalke , Allgäuer M, Schuierer G, Koch H, Schlaier J, Ulrich W, Brawanski A, Bogdahn U, Steinbrecher A: Salvage Therapy in patients with glioblastoma. Is there any benefit?. Cancer. 2003, 98: 2678-86. 10.1002/cncr.11845.View ArticlePubMedGoogle Scholar
  13. Nieder C, Grosu AL, Molls M: A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev. 2000, 26: 397-409. 10.1053/ctrv.2000.0191.View ArticlePubMedGoogle Scholar
  14. Dhermain F, de Crevoisier R, Parker F, Cioloca C, Kaliski A, Beaudre A, Lefkopoulos D, Armand JP, Haie-Meder C: Role of radiotherapy in recurrent gliomas [French]. Bull Cancer. 2004, 91: 883-889.PubMedGoogle Scholar
  15. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/5/55/prepub

Copyright

© Vordermark et al; licensee BioMed Central Ltd. 2005

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement